Neurotech Solutions
Cutting edge cloud-based technologies focused on human cognition and behavior with a special emphasis on attentional disorders.
Unleashing the power of personalized attention profiling
to enable talents to fulfil their potential
About Us
We strive to provide advanced solutions to help improve people’s everyday
functioning, well-being, academic abilities and achievements.
MOXO d-CPT
MOXO d-CPT is the industry’s leading fully online and cloud based, validated Continuous Performance Test (CPT). MOXO is backed by clinical trials, and 100+ peer-reviewed scientific publications. Used by numerous institutes and clinics worldwide (B2B2C), MOXO provides an objective and detailed assessment for the screening and diagnosis of attention difficulties and deficits.
Our Impact
We believe accurate attentional profiling can assist decision makers and care takers in finding the best solutions and action plans to enable talents to achieve their full potential.
It has also been shown that early ADHD identification and help reduce crime, increase quality of life, and even save lives for millions across the world.
MOXOedu
As schools using personalized-learning approaches continue to make greater gains in math and reading, reduce dropouts, and achieve higher grade averages, it is no surprise that personalized adaptive learning and social-emotional learning (SEL) are a high priority for teachers and education specialists.
MOXOedu is the first scientifically-based assessment of learners׳ attentional profiling, providing, empowering educators to build a cohesive environment in which all learners can utilize their best learning strategy and thrive.
MOXO d-CPT
MOXO d-CPT is the industry’s leading fully online and cloud based, validated Continuous Performance Test (CPT). MOXO is backed by clinical trials, and 100+ peer-reviewed scientific publications. Used by numerous institutes and clinics worldwide (B2B2C), MOXO provides an objective and detailed assessment for the screening and diagnosis of attention difficulties and deficits.
MOXOedu
As schools using personalized-learning approaches continue to make greater gains in math and reading, reduce dropouts, and achieve higher grade averages, it is no surprise that personalized adaptive learning and social-emotional learning (SEL) are a high priority for teachers and education specialists.
MOXOedu is the first scientifically-based assessment of learners׳ attentional profiling, providing, empowering educators to build a cohesive environment in which all learners can utilize their best learning strategy and thrive.
Our Impact
We believe accurate attentional profiling can assist decision makers and care takers in finding the best solutions and action plans to enable talents to achieve their full potential.
It has also been shown that early ADHD identification and help reduce crime, increase quality of life, and even save lives for millions across the world.
Awards and prizes
Israel Innovation
Authority IIA
Awarded a monetary prize to research development plan for improve processes in governmental offices. Machine learning bases on our data to predict the right medication and dosage – Personalisation of ADHD medication
SMEi phase 1 -
Horizon 2020 EU
Prize awarded for a business feasibility study – for Seemee mobile, self-assessment application for screening ADHD, utilizing CPT and event tracking
1st prize - Harel insurance with Tokio Marine
Technological solution for insurance companies recommending preventative measure for decreasing car accidents by screening young ADHD drivers for attentiveness influences of driving.
Top 10 of South summit
Innovation is business contest
presentation in the Summit – Seemobile, mobile based screening tool for ADHD utilizing CPT and eyetracking as a biomarker
Advisory Board
We are committed to our shareholders to excel in all performance, pushing forward boundaries of possibility and rigorously expanding our activities worldwide.
Dr.
Jacob (Yaki) Dayan
CEO
Dr. Dayan is an EdTech visionary, ecosystem builder, and a recognized expert in education innovation and entrepreneurship. Dr. Dayan founded EdTech Israel in 2014 with the vision to transform startup-nation to EdTech-nation.
EdTech Israel is a nationwide, unbiased, independent social impact business that successfully connects the Israeli ecosystem with international markets.
Dr. Dayan is also the CEO of Neurotech Solutions . With expertise in attentional profiling and analytics, Neurotech Solutions is a new leader in the field of attention. For the education and learning sectors, Neurotech is the industry’s first cloud-based assessment available for the attention profiling of students and learners.
Dr. Dayan holds a BSc in Electronics Engineering from the well-renowned Technion in Haifa (1982), and a PhD in Education from the University of Haifa (2014).
Prof.
César Soutullo, MD,
Scientific Board
Prof. César Soutullo is Professor of Psychiatry and Director of ADHD Outpatient Program at The University of Texas Health Science Center in Houston, Texas, USA, McGovern Medical School, at the Louis A. Faillace MD Department of Psychiatry and Behavioral Sciences.
He moved there in 2019, after working 20 years as Director of the Child & Adolescent Psychiatry (CAP) Unit, and Training Director of the CAP Fellowship program at the University of Navarra Clinic, in Pamplona, Spain.
Prof. Soutullo graduated from the Complutense University of Madrid College of Medicine, Spain. After two years of general training (Intern al Medicine, Surgery & Emergency Medicine) in the U.K., he completed his Residency in Psychiatry, and Fellowships in Biological Psychiatry and Child & Adolescent Psychiatry at the University of Cincinnati, Ohio, USA., where he then was Assistant Professor in Clinical Psychiatry.
He completed his PhD at the University of Navarra (2002), in Psychiatry & Neurosciences and his dissertation on Phenomenology of Children at High Risk for Bipolar Disorder obtained the “Extraordinary Thesis Award”.
He received awards such as the AACAP Presidential Scholar Award, the Association for Academic Psychiatry Bristol-Myers Fellowship in Academic Psychiatry, and the Society of Biological Psychiatry Eli Lilly Fellowship Award, and has been Mentor twice in the Donald J. Cohen Fellowship.
His main research interests are ADHD, pediatric mood disorders (especially bipolar), and pediatric psychopharmacology, with research funding from national and international private and public sources. He is member of EUNETHYDIS´ Guidelines Group and of the Scientific Program Committee of the World Federation of ADHD.
Prof. Soutullo is a reviewer of 29 international journals, and is author of 98 original reports, 108 book chapters, 241 abstracts at national or international conferences and has authored or edited 22 books (H Factor: 28), and has been invited to give hundreds of talks at National and international conferences/meetings/courses.
Sam Goldstein
Sam Goldstein
Sam Goldstein
Sam Goldstein
Scientific Board
Sam Goldstein, PhD is an Adjunct Assistant Professor at the University of Utah School of Medicine. He currently serves as Editor-in-Chief of the Journal of Attention Disorders and sits on the editorial boards of 6 peer reviewed journals.
Dr. Goldstein has authored over 50 trade and science texts as well as over 36 science-based book chapters and 30 peer reviewed research articles. He has also co-authored ten psychological tests.
He is the Clinical Director of the Neurology Learning and Behavior Center. The center conducts evaluations, consultation and provides treatment services to 300 individuals and families each year.
He is co-editor of the Encyclopedia of Child Development. Recent books include the Handbook of Intelligence: Evolutionary Theory, Historical Perspective and Current Concepts, Handbook of Resilience – 2nd Edition, Raising Resilient Children with Autism Spectrum Disorders, Handbooks of Neurodevelopmental and Genetic Disorders in Children and Adults, Assessment of Intelligence and Achievement, Assessment of Autism Spectrum Disorders, Handbook of Executive Functioning, Assessment of Impairment and Managing Children’s Classroom Behavior: Creating Sustainable Resilient Classrooms. He is the co-author of the Autism Spectrum Rating Scales, Comprehensive Executive Functioning Inventory, Rating Scales of Impairment and the Cognitive Assessment System Second Edition.
He has lectured to thousands of professionals and the lay public in the U.S., South America, Asia, Australia and Europe.
Our Team
Our employees are part of our family. We encourage our employees to make a difference in society by taking a personal interest in what the company is engaged with. We listen to our employees, valuing the contribution each employee brings to the table, and their unique perspective on things. We nourish effective cross-function teamwork that plans well, engage in innovative thinking processes and executes to target. We want our employees to smile on their way to work to feel appreciated, to be well remunerated and to passionately give their heart and mind to the organization.
Roni Bochman-Ronen
Marketing Director
I am passionate about all things marketing related. But having a good and worthy product to work with brings gratification and a sense of purpose to life. Working with Neurotech solutions’ MOXO is just that kind of product. I feel I am doing something good for someone where in the world everyday.
Aviram Salomon
Product & Regulatory Director
For me Neurotech is my second house. After 11 years and still counting in the company I know that we make positive change in the field of ADHD and actually effect on the life of our end users.
I am proud to be the product manager of MOXO.
Megi Franko
HR, Administration Manager
I am the office manager at Neurotech Solutions, and have many years of experience at employee management, procurement, accounting and sales. I support all training and sales process in Israel and abroad for MOXO, and help administer tests.
I Love my work. The MOXO team and the MOXO test.
2021 Ⓒ Neurotech Solutions Ltd.
Ver: 201609 | ISO 13485:2016 certified
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 877041
In the United States ONLY, MOXO™ d-CPT should be used for cognitive assessment of attention and executive functions, and is not indicated for ADHD diagnosis
UX/UI Three Bears Development Site-Pro
